MX2020001046A - Composicion inmunogenica que comprende un peptido de fusion derivado de toxoides de superantigenos. - Google Patents

Composicion inmunogenica que comprende un peptido de fusion derivado de toxoides de superantigenos.

Info

Publication number
MX2020001046A
MX2020001046A MX2020001046A MX2020001046A MX2020001046A MX 2020001046 A MX2020001046 A MX 2020001046A MX 2020001046 A MX2020001046 A MX 2020001046A MX 2020001046 A MX2020001046 A MX 2020001046A MX 2020001046 A MX2020001046 A MX 2020001046A
Authority
MX
Mexico
Prior art keywords
immunogenic composition
peptide derived
fusion peptide
superantigen
toxoids
Prior art date
Application number
MX2020001046A
Other languages
English (en)
Inventor
Mohammad Javad Aman
Thomas Kort
Nils Williston
Arundhathi Venkatasubramaniam
Rajan Prasad Adhikari
Frederick W Holtsberg
Original Assignee
Integrated Biotherapeutic Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Integrated Biotherapeutic Vaccines Inc filed Critical Integrated Biotherapeutic Vaccines Inc
Publication of MX2020001046A publication Critical patent/MX2020001046A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente descripción proporciona composiciones inmunogénicas útiles en la prevención y tratamiento de una infección por Staphylococcus aureus; en particular, la descripción proporciona oligopéptidos multivalentes, proteínas de fusión que comprenden dos o más proteínas de superantígeno (SAg) estafilocócico o cualquier fragmento, variantes o derivados de estos fusionados entre sí como un polipéptidos únicos en cualquier orden.
MX2020001046A 2017-07-27 2018-07-25 Composicion inmunogenica que comprende un peptido de fusion derivado de toxoides de superantigenos. MX2020001046A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762537706P 2017-07-27 2017-07-27
PCT/US2018/043687 WO2019023341A1 (en) 2017-07-27 2018-07-25 IMMUNOGENIC COMPOSITION COMPRISING A MELTING PEPTIDE DERIVED FROM TOXOIDS OF SUPERANTIGENES

Publications (1)

Publication Number Publication Date
MX2020001046A true MX2020001046A (es) 2020-08-06

Family

ID=65041106

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020001046A MX2020001046A (es) 2017-07-27 2018-07-25 Composicion inmunogenica que comprende un peptido de fusion derivado de toxoides de superantigenos.

Country Status (7)

Country Link
US (2) US11260120B2 (es)
EP (1) EP3658181A4 (es)
JP (1) JP7303791B2 (es)
CN (1) CN110996993B (es)
CA (1) CA3069747A1 (es)
MX (1) MX2020001046A (es)
WO (1) WO2019023341A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116497003A (zh) * 2023-06-29 2023-07-28 北京百普赛斯生物科技股份有限公司 一种从溶液中纯化目标蛋白的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593114B1 (en) 1996-01-05 2003-07-15 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
US6713284B2 (en) * 1997-06-25 2004-03-30 The United States Of America As Represented By The Secretary Of The Army Bacterial superantigen vaccines
US7087235B2 (en) 1997-06-25 2006-08-08 The United States Of America As Represented By The Secretary Of The Army Fusion protein of streptococcal pyrogenic exotoxins
EP1097212B1 (en) 1998-07-10 2008-12-24 U.S. Medical Research Institute of Infectious Diseases Anthrax vaccine
SE0102327D0 (sv) 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
GB0118155D0 (en) 2001-07-25 2001-09-19 Lorantis Ltd Superantigen
CA2506538C (en) 2001-11-26 2013-07-09 Robert G. Ulrich Bacterial superantigen vaccines
AU2004220590B2 (en) 2003-03-07 2010-02-18 Inhibitex, Inc. Polysaccharide - Staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
US7754225B2 (en) 2006-07-20 2010-07-13 Glaxosmithkline Biologicals S.A. Method of protecting against staphylococcal infection
WO2008154101A1 (en) 2007-06-06 2008-12-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Psm peptides as vaccine targets against methicillin-resistant staphylococcus aureus
CA2697538C (en) 2007-08-31 2019-02-12 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
WO2012109167A1 (en) 2011-02-08 2012-08-16 Integrated Biotherapeutics, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides
WO2012170097A2 (en) 2011-03-16 2012-12-13 Regents Of The University Of Minnesota Compositions and methods for inducing immune responses against bacteria in the genus staphylococcus
EP2785368B1 (en) 2011-12-02 2019-03-13 Integrated Biotherapeutics, Inc. Immunogenic composition comprising panton-valentine leukocidin (pvl) derived polypeptides
DK3010535T3 (da) 2013-06-19 2020-11-30 Integrated Biotherapeutics Inc Toxoide peptider afledt fra fenol opløselige modulin, delta toxin, superantigener og fusioner deraf

Also Published As

Publication number Publication date
US20200206335A1 (en) 2020-07-02
CA3069747A1 (en) 2019-01-31
CN110996993A (zh) 2020-04-10
JP2020537488A (ja) 2020-12-24
CN110996993B (zh) 2024-05-31
US11826412B2 (en) 2023-11-28
EP3658181A4 (en) 2021-06-16
US11260120B2 (en) 2022-03-01
JP7303791B2 (ja) 2023-07-05
EP3658181A1 (en) 2020-06-03
WO2019023341A1 (en) 2019-01-31
US20220257744A1 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
AU2017263237A1 (en) GDF15 fusion proteins and uses thereof
AU2018243910A8 (en) A multiple antigen presenting system (MAPS)-based staphylococcus aureus vaccine, immunogenic composition, and uses thereof
MX350170B (es) Composición inmunogénica estable de antígenos de staphylococcus aureus.
EP3684168A4 (en) FUSION PROTEINS, RECOMBINANT BACTERIA AND EXOSPORIUM FRAGMENTS FOR PLANT HEALTH
MX2020005170A (es) Formulaciones de proteinas de fusion vegfr-fc.
EA201990451A1 (ru) Композиция многовалентных пневмококковых конъюгатов капсульного полисахарида с белком-носителем и ее применение
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
PH12017500450A1 (en) Flavivirus virus like particle
PE20161406A1 (es) Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas
WO2015031778A3 (en) Compositions and methods for the treatment or prevention of tuberculosis
MX2020006328A (es) Composición inmunogénica.
MX2019015007A (es) Composiciones inmunogénicas que comprenden los polipéptidos derivados de la leucocidina de staphylococcus aureus luka y lukb.
WO2018132696A3 (en) Stomach acid-stable and mucin-binding protein-polymer conjugates
WO2018136698A3 (en) Bone-targeting antibodies
EP3498847A4 (en) VACCINE COMPOSITION FOR PREVENTING SWINE MYCOPLASM INFECTION COMPRISING A RECOMBINANT PROTEIN
MX2020001046A (es) Composicion inmunogenica que comprende un peptido de fusion derivado de toxoides de superantigenos.
MX2021002909A (es) Vacunas de proteinas de fusion neumococicas.
MX2017015375A (es) Variantes de oxintomodulina pegilada.
MX2018000023A (es) Particulas semejantes a virus recombinantes que utilizan la proteina gag del virus de inmunodeficiencia bovina.
IL277632A (en) CDNF fragments from the carboxyl end, pharmaceutical compositions containing them and their uses
PH12020551618A1 (en) Erenumab compositions and uses thereof
EP3475418A4 (en) TATK-CDKL5-FUSION PROTEINS, COMPOSITIONS, FORMULATIONS AND USE THEREOF
MX2015002279A (es) Peptido pntx(19) sintético, composición farmacéutica.y uso.
EP3802573A4 (en) VACCINE COMPOSITION WITH RECOMBINANT PROTEIN OF ATTENTIONED ENTEROTOXIN AND CYTOTOXIN FROM STAPHYLOCOCCUS AUREUS
MX2022004061A (es) Peptidos de estafilococo y metodos de uso.